Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia

Neurological Sciences

Volumn 29, Issue 6, 2008, Pages 417-423

  Ravaglia, Sabrina ^a   Bini, Paola ^a   Sinforiani, Elena ^a   Franciotta, Diego ^b   Zardini, Elisabetta ^b   Tosca, Pietro ^a   Moglia, Arrigo ^a   Costa, Alfredo ^b  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Alzheimer's disease; Biological markers; Cerebrospinal fluid; Tau protein; Vascular dementia

Indexed keywords

TAU PROTEIN; THREONINE;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIINFARCT DEMENTIA; PREDICTION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; CATALYTIC DOMAIN; COGNITION DISORDERS; DEMENTIA, VASCULAR; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURONS; NEUROPSYCHOLOGICAL TESTS; PHOSPHORYLATION; TAU PROTEINS; THREONINE;

EID: 58149085383     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-008-1023-1     Document Type: Article

References (30)

1. Ferri CP, Prince M, Brayne C et al (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112-2117
2. McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of health and human services task force on Alzheimer's disease. Neurology 34:939-944
3. Goedert M (1993) Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 16:460-465
4. Buée L, Bussiere T, Buée-Scherrer V et al (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 33:95-130
5. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phophorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103:26-35
6. Andreasen N, Vanmechelen E, Vanderstichele H et al (2003) Cerebrospinal fluid levels of total-Tau, phospho-Tau and A 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand 107[Suppl 179]:47-51
7. Andreasen N, Blennow K (2005) CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 107:165-173
8. Blennow K, Wallin A, Ögren H et al (1995) Tau protein in cerebrospinal fluid: A biochemical diagnostic marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 26:231-245
9. Hulstaert F, Blennow K, Ivanoiu A et al (1999) Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52:1555-1562
10. Andreasen N, Hesse C, Davidsson P et al (1999) Cerebrospinal fluid -amyloid(1-42) in Alzheimer's disease: Differences between early- and late-onset alzheimer disease and stability during the course of disease. Arch Neurol 56:673-680
11. Otto M, Wiltfang J, Tumani H et al (1997) Elevated levels of tauprotein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 225:210-212
12. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2:605-613
13. Hampel H, Buerger K, Zinkoswski R et al (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer's Disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry 61:95-102
14. Bibl M, Mollenhauer B, Esselmann H et al (2008) Cerebrospinal fluid neurochemical phenotypes in vascular dementias: Original data and mini-review. Dement Geriatr Cogn Disord 25:256-265
15. Roman GC, Tatemichi TK, Erkinjuntti T et al (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250-260
16. Folstein ME, Folstein SE, McHugh PR (1975) Mini-mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12:189-198
17. Tibbling G, Link H, Ohman S (1977) Principles of albumin and IgG analyses in neurological disorders. Establishment of reference values. Scand J Clin Lab Investig 37:385-390
18. Vanmechelen E, Vanderstichele H, Davidsson P et al (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285:49-52
19. Itoh N, Arai H, Urakami K et al (2001) Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 50:150-156
20. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B et al (2003) Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to betaamyloid peptide 42. Arch Neurol 60:1202-1206
21. Buerger K, Zinkowski R, Teipel SJ et al (2002) Differential diagnosis of Alzheimer's disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59:1267-1272
22. Sjögren M, Davidsson P, Tullberg M et al (2001) Both total and hyperphosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 70:624-630
23. Jellinger KA (1996) Diagnostic accuracy of Alzheimer's disease. A clinicopathological study. Acta Neuropathol 91:219-220
24. Holmes C, Cairns N, Lantos P, Mann A (1999) Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 174:45-50
25. Lim A, Tsuang D, Kukull W et al (1999) Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc 47:564-569
26. Jellinger KA (2008) The pathology of "vascular dementia": A critical update. J Alzheimers Dis 14:107-123
27. Knopman DS, DeKosky ST, Cummings JL et al (2001) Practice parameter: diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1143-1153
28. Walhund L, Blennow K (2003) Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 339:99-102
29. De Leon MJ, Desanti S, Zinkowski R et al (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 3:394-401
30. Wallin AK, Blennow K, Andreasen N, Minthon L (2006) CSF biomarkers for Alzheimer's disease: Levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 3:131-138